Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study

Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study

Abstract Background Historically, high hepatocellular carcinoma (HCC)–related mortality has been, in part, due to lack of effective therapies; however, several systemic therapies have been recently approved for HCC treatment, including regorafenib and ramucirumab. These two treatments utilize differ...

Full description

Bibliographic Details
Main Authors: Neehar D. Parikh, Allicia Girvan, Joshua Coulter, Jonathon Gable, Jiat Ling Poon, Sangmi Kim, Anindya Chatterjee, Marco Boeri
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
Patient preferences
Threshold technique
Direct-elicitation
Online Access:https://doi.org/10.1186/s12885-022-10388-8

Internet

https://doi.org/10.1186/s12885-022-10388-8

Similar Items